The art of distraction: Why sometimes we avoid ‘cancer talk’
There is an unspoken rule that seems to apply to all cancer caregivers. It goes something like this: You should always be serious, present, and…
Myeloma
Lynozyfic wins FDA accelerated approval for treating RRMM adults
Linvoseltamab, now branded as Lynozyfic, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for treating adults with relapsed or refractory…
Recognizing the invisible labor we perform as caregivers
I have 27 browser tabs open on my laptop and 33 on my phone. They range from grocery lists with foods low in sodium to…
EU panel backs 1st-line Sarclisa for transplant-eligible myeloma
A European Medicines Agency committee has recommended that Sarclisa (isatuximab), used in combination with standard-of-care medications, be approved for the treatment of adults newly…
As a caregiver, I’m always on the lookout for myeloma research news
The word “caregiver” usually conjures up images of hands-on support: providing comfort, helping out with everyday tasks, and managing medications. However, for those of us…
EU panel backs Darzalex for high-risk smoldering multiple myeloma
A European Medicines Agency (EMA) committee recommended that Darzalex (daratumumab) given as an under-the-skin injection be approved for people with smoldering multiple myeloma (SMM)…
When words fail: The silence that falls after a myeloma diagnosis
I still remember what happened in 2022 after my mother received her myeloma diagnosis. I was sitting by her side in the hospital room.
Combination myeloma treatment shows promise in trial
Most people with hard-to-treat multiple myeloma who were given a combination treatment of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) in a clinical trial were alive…
Why I continue to write about my experience as a caregiver
“Nobody is reading any of those essays you caregivers write,” a healthcare provider once told me. The following week, a stranger emailed me: “Your…
Patients in cell therapy Carvykti trial in remission after 5 years
One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion of the cell therapy Carvykti…
